Literature DB >> 17667190

Amantadine for adynamic speech: possible benefit for aphasia?

Anna M Barrett1, Paul J Eslinger.   

Abstract

OBJECTIVE: Dopaminergic agents may stimulate behavior and verbal expression after frontal lobe dysfunction. Although amantadine is used in neurorehabilitation of motivational disorders and head injury, it is not commonly prescribed to improve aphasia. This pilot study examined verbal fluency on and off amantadine for nonfluent speech.
DESIGN: Four participants undergoing inpatient rehabilitation, meeting criteria for transcortical motor aphasia had stroke (2), stroke postaneurysm surgery (1), or brain tumor resection (1). We administered 100 mg of amantadine twice a day in an open-label, on-off protocol, with multiple assessments per on-off period.
RESULTS: Off medication, subjects generated a mean 12.62 of words (abnormally few) on the Controlled Oral Word Association test. On medication, word generation significantly improved to 17.71 words (P = 0.04), although scores remained psychometrically in the abnormal range.
CONCLUSIONS: Further research on amantadine, specifically for nonfluent speech and nonfluent aphasia, including effects on functional communication and control conditions, may be warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17667190      PMCID: PMC1939971          DOI: 10.1097/PHM.0b013e31811473b3

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  25 in total

Review 1.  Amantadine and other antiglutamate agents: management of Parkinson's disease.

Authors: 
Journal:  Mov Disord       Date:  2002       Impact factor: 10.338

Review 2.  Pharmacological treatment for aphasia following stroke.

Authors:  J Greener; P Enderby; R Whurr
Journal:  Cochrane Database Syst Rev       Date:  2001

3.  Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy.

Authors:  David B Arciniegas; Kimberly L Frey; C Alan Anderson; Kristin M Brousseau; Susie N Harris
Journal:  Brain Inj       Date:  2004-12       Impact factor: 2.311

4.  An open-label trial of bromocriptine in nonfluent aphasia: a qualitative analysis of word storage and retrieval.

Authors:  M Gold; D VanDam; E R Silliman
Journal:  Brain Lang       Date:  2000-09       Impact factor: 2.381

Review 5.  Review of awakening agents.

Authors:  Ryan DeMarchi; Vikas Bansal; Anthony Hung; Karol Wroblewski; Hemi Dua; Sanjeev Sockalingam; Shree Bhalerao
Journal:  Can J Neurol Sci       Date:  2005-02       Impact factor: 2.104

Review 6.  Psychostimulant use in the rehabilitation of individuals with traumatic brain injury.

Authors:  John Whyte; Monica Vaccaro; Patricia Grieb-Neff; Tessa Hart
Journal:  J Head Trauma Rehabil       Date:  2002-08       Impact factor: 2.710

7.  Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial.

Authors:  Jay M Meythaler; Robert C Brunner; Alice Johnson; Thomas A Novack
Journal:  J Head Trauma Rehabil       Date:  2002-08       Impact factor: 2.710

8.  The use of dopamine enhancing medications with children in low response states following brain injury.

Authors:  P D Patrick; M L Buck; M R Conaway; J A Blackman
Journal:  Brain Inj       Date:  2003-06       Impact factor: 2.311

Review 9.  Treatment of adynamia in aphasia.

Authors:  Anastasia M Raymer
Journal:  Front Biosci       Date:  2003-09-01

Review 10.  Amantadine for fatigue in multiple sclerosis.

Authors:  C Taus; G Giuliani; E Pucci; R D'Amico; A Solari
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  10 in total

1.  Pharmaceuticals for poststroke and brain injury rehabilitation.

Authors:  Anna M Barrett; Charles E Levy; Leslie J Gonzalez Rothi
Journal:  Am J Phys Med Rehabil       Date:  2007-08       Impact factor: 2.159

2.  Poststroke and brain injury rehabilitation treatment strategies.

Authors:  Anna M Barrett; Charles E Levy; Leslie J Gonzalez Rothi
Journal:  Am J Phys Med Rehabil       Date:  2007-09       Impact factor: 2.159

3.  Rehabilitation after stroke: current state of the science.

Authors:  Alex R Carter; Lisa T Connor; Alexander W Dromerick
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

4.  Psycholinguistics of Aphasia Pharmacotherapy: Asking the Right Questions.

Authors:  Dalia Cahana-Amitay; Martin L Albert; Abigail Oveis
Journal:  Aphasiology       Date:  2014-01-01       Impact factor: 2.773

Review 5.  Neuroscience insights improve neurorehabilitation of poststroke aphasia.

Authors:  Marcelo L Berthier; Friedemann Pulvermüller
Journal:  Nat Rev Neurol       Date:  2011-02       Impact factor: 42.937

Review 6.  Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic Review.

Authors:  David J Gagnon; Angela M Leclerc; Richard R Riker; Caitlin S Brown; Teresa May; Kristina Nocella; Jennifer Cote; Ashley Eldridge; David B Seder
Journal:  Neurocrit Care       Date:  2020-08       Impact factor: 3.210

Review 7.  Drug therapy of post-stroke aphasia: a review of current evidence.

Authors:  Marcelo L Berthier; Friedemann Pulvermüller; Guadalupe Dávila; Natalia García Casares; Antonio Gutiérrez
Journal:  Neuropsychol Rev       Date:  2011-08-16       Impact factor: 7.444

8.  Integrated Discourse Therapy After Glioblastoma: A Case Report of Face-To-Face and Tele-NeuroRehabilitation Treatment Delivery.

Authors:  Lisa Milman; Emma Anderson; Katelyn Thatcher; Deborah Amundson; Chance Johnson; Morgan Jones; Louie Valles; Dale Willis
Journal:  Front Neurol       Date:  2020-11-19       Impact factor: 4.003

Review 9.  The Potential Role of Voltage-Dependent Anion Channel in the Treatment of Parkinson's Disease.

Authors:  Yajie He; Wenjun Wang; Ting Yang; Elizabeth Rosalind Thomas; Rongyang Dai; Xiang Li
Journal:  Oxid Med Cell Longev       Date:  2022-10-05       Impact factor: 7.310

Review 10.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.